Back to Blog
An illustrative liver teaching model
Illustrative AI-generated image; not an actual product or patient.

GLP-1s for Fatty Liver Disease: What the Evidence Shows

Updated •2 min readHealth Guides

Fatty liver, MASH and advanced liver disease are different clinical situations. Wegovy’s current label includes a specific MASH indication, so an older statement that every GLP-1 use is investigational needs correction.

GLP-1 Brands & Reviews

  1. CoreAge Rx offers clinician-reviewed compounded weight care. Compare the annual offer from $79/month for semaglutide or $129/month for tirzepatide with the full payment, dispensing details and refund conditions.

    Semaglutide from $79/mo · Tirzepatide from $129/mo

    Published

    • Online prescribing and pharmacy fulfillment
    • Dated first-party sources in the review

    Questions to resolve

    • Confirm full medication and care cost
    • Verify local eligibility and ongoing support
  2. SuperHealthy Rx advertises compounded semaglutide at $85/month and tirzepatide at $135/month, with a provider visit and shipping included. Confirm the current offer, billing term and state eligibility.

    Semaglutide: $85/month advertised · Tirzepatide: $135/month advertised

    Published

    • Online prescribing and pharmacy fulfillment
    • Dated first-party sources in the review

    Questions to resolve

    • Confirm full medication and care cost
    • Verify local eligibility and ongoing support
  3. Likeness Rx offers online access to compounded semaglutide and tirzepatide. Its public page lists semaglutide from $79/month; tirzepatide from $129/month.

    Semaglutide from $79/month · Tirzepatide from $129/month

    Published

    • Online prescribing and pharmacy fulfillment
    • Dated first-party sources in the review

    Questions to resolve

    • Confirm full medication and care cost
    • Verify local eligibility and ongoing support
  4. Henry describes cash-pay plans bundling visits, medicine, supplies and ongoing care. Its multi-month cancellation terms can differ from its monthly plans.

    Complete current quote needed

    Published

    • Telehealth and weight care
    • Dated first-party sources in the review

    Questions to resolve

    • Confirm full medication and care cost
    • Verify local eligibility and ongoing support
  5. Hims currently publishes a weight-loss membership with approved product options and medication billed separately. Older compounded-only descriptions do not capture its current offer.

    Membership, medicine extra

    Published

    • Telehealth and weight care
    • Dated first-party sources in the review

    Questions to resolve

    • Confirm full medication and care cost
    • Verify local eligibility and ongoing support

Publisher preference scores. Comparison method and commercial relationships.

At a glance

  • Confirm the diagnosis and fibrosis stage rather than relying on a liver-enzyme result alone.
  • The Wegovy MASH indication is product-specific and subject to the label’s conditions.
  • Advanced disease requires coordinated specialist care.

Begin with the liver diagnosis

MASLD refers to metabolic dysfunction-associated steatotic liver disease. MASH includes inflammatory liver injury; fibrosis describes scarring. These distinctions matter because an effective weight-management medicine is not automatically an appropriate treatment for every liver stage.

A hepatology team may use blood tests, imaging and other assessments to establish severity and monitor change. A generic online weight questionnaire cannot substitute for that evaluation.

Sources: Wegovy prescribing informationNIDDK: prescription medications for weight management

Read the current indication

The current Wegovy prescribing information describes treatment of noncirrhotic MASH with moderate to advanced fibrosis in adults under accelerated approval. Read the exact population, limitations and follow-up requirements in the current label.

Do not transfer this indication to oral semaglutide, another GLP-1 product or a compounded preparation without the corresponding evidence and authorization.

Sources: Wegovy prescribing informationNIDDK: prescription medications for weight management

Care continues beyond the initial weight change

Discuss how the liver condition, diabetes, cardiovascular risk and nutrition will be followed together. Avoid advice that turns a complex condition into a simple choice of the cheapest subscription.

Sources: Wegovy prescribing informationNIDDK: prescription medications for weight management

Sources and review boundaries

Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.

  1. Wegovy prescribing informationMedical or regulatory source · Source reviewed ·
  2. NIDDK: prescription medications for weight managementMedical or regulatory source · Source reviewed ·

By Chief Medical Correspondent. Original publication date was not recorded. Updates are recorded when content changes.